Overview

Raltegravir-based Antiretroviral Therapy for Resistant HIV-1 Infection

Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety and efficacy of RAL-based regimen in treatment-experienced patients with resistant HIV infection
Phase:
N/A
Details
Lead Sponsor:
Peking Union Medical College
Treatments:
Raltegravir Potassium